RxDoctor Payments Data

Nathan Massey, MD

Gastroenterology · Lexington, KYNPI 1891865135

Payments from drug & device makers

$1,896in general payments, 2019–2025

Across 80 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$246
  • Janssen Scientific Affairs, LLC$227
  • Pfizer$50
  • Nestle Healthcare Nutrition Inc.$49
  • Axonics, Inc.$49
  • plus $214 from 9 others

What the payments were for

  • Food & beverage$1,88299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,896 in reported general payments places this provider in the 35th percentile of 207 gastroenterology providers in Kentucky.

See all gastroenterology providers in Kentucky

Medicare billing

Part B allowed, 2024
$250,385
Medicare patients
404
Services billed
7,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab63$1,773,522
CreonLipase/Protease/Amylase99$344,472
XifaxanRifaximin18$56,479
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres15$51,510
LinzessLinaclotide33$30,552
Mesalamine20$21,166
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates265$18,250
Colestipol Hcl102$9,340
Alosetron Hcl13$7,036
Mesalamine ErMesalamine19$7,034
Budesonide EcBudesonide11$6,589
Dexlansoprazole DrDexlansoprazole25$6,462
Esomeprazole Magnesium283$5,352
Ursodiol29$4,886
Pantoprazole Sodium346$4,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$246$1,773,52263 claims
AbbVieCreon, Linzess$1,061$375,024132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 207 gastroenterology providers in Kentucky.

Other gastroenterology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →